Multiple inflammation and fibrosis-related targets

The phrase "multiple inflammation and fibrosis-related targets" describes a heterogeneous group of molecular entities, including cytokines (e.g., TNF, TGF-β), growth factors, kinase enzymes, cell surface receptors, and signaling pathway components involved in *inflammation* and *fibrosis* processes across various organs. These targets mediate immune cell activation, extravasation, myofibroblast activation, extracellular matrix deposition, and tissue remodeling. Because many molecules and pathways contribute to both inflammation and fibrogenesis, therapeutic strategies frequently aim for several molecular targets at once, especially in diseases like idiopathic pulmonary fibrosis, liver fibrosis, and chronic kidney disease. Drugs such as pirfenidone, nintedanib, ruxolitinib, and monoclonal antibodies targeting TGF-β or TNF exemplify this multi-target approach[3][4][5][7]. The term is overly broad for precise biomolecular classification, does not specify a unique protein or receptor, and thus is not suitable for the requested structured target database entry.

TGF-β signaling inhibition, JAK/STAT pathway inhibition, Immunomodulation, Anti-inflammatory, Inhibition of growth factor signaling, MMP inhibition